Abstract
In November 2008, China announced a major economic stimulus package, including
$124bn to be spent on healthcare. These changes will have a major impact on
the Chinese pharmaceutical landscape over the next 15 years, as the stimulus
increases the number of clinics in rural areas, dissociates pharmacies from
hospitals and promises healthcare coverage to 100% of the population by 2020.
This report - Chinese Pharmaceutical Market Outlook 2009-2024 - analyses
prospects for the pharma market and industry sector in China. This new study
discusses market drivers and restraints such as production capacity,
intellectual property rights and the high, fast-growing healthcare demands in
China. Importantly, we provide detailed sales forecasting at the core of the
analyses.
As both a large producer and consumer of a wide range of medicines, China is
now a crucial player in the global pharmaceutical market and industry. China
is still a challenging environment for foreign companies, investors and
purchasers. Will the great potential benefits offered by China outweigh its
drawbacks as a pharma market? Yes they will - but how and why? Read this
report to find out.
China' s rising significance in the global pharma market will make it a vital
market for international pharmaceutical companies to enter and expand. China' s
efforts to reinvent its healthcare system will change the way pharmaceuticals
are marketed and sold throughout the country. However, those changes will not
take place immediately. What will happen first? For example, how will
prescription of antibiotics change? Also, what impact will reported quality
concerns and counterfeiting have on China' s pharmaceutical sector?
Comprehensive analysis of the Chinese pharma sector
Chinese Pharmaceutical Market Outlook 2009-2024 examines that sector
critically, through a comprehensive review of information sources. This report
provides detailed sales forecasts, discussions of developments and analyses of
commercial drivers and restraints, including a SWOT analysis. There are over
70 tables and figures and a full interview transcript from our survey. The
result is a comprehensive market- and industry-centred report, with detailed
analyses and informed opinion to benefit your work.
Why you should buy Chinese Pharmaceutical Market Outlook 2009-2024
In this report you will receive the following benefits in particular:
- Sales forecasts for the overall Chinese pharma market from 2009 to 2024
- Sales forecasts for top-selling drug categories in that market from 2009
to 2024
- Comprehensive discussions to support the forecasts, including SWOT
analysis and discussions of market drivers and restraints
- Forecasts for prescription drugs, branded drugs, generics,
over-the-counter treatments and the clinical trials market in China
- Expert opinion from our original survey on emerging medical trends in
China.
Crucial questions answered by this report:
This report answers important questions such as:
- What are the highest-selling drug types in China and how will their sales
develop from 2009 onwards?
- How will the healthcare stimulus affect sales of diabetes medicines by
2014?
- Which companies are investing in China? What types of investments are they
making?
- What is China' s scientific and technological expertise like?
- What domestic pharma companies are making promising developments, and what
do their business models suggest about China' s pharma industry?
- What does China' s research and development landscape look like for pharma?
- Why is China such an important research and development environment for
stem cells technologies?
- What is the generic drug penetration in China? How will market shares for
original-branded and generic drugs change from 2009 onwards?
- Why are clinical trials moving to China, and how will that market develop?
| 
View Cart
